Background: Permanent low-dose-rate brachytherapy (BT) with iodine 125 is an established curative treatment for localized prostate cancer. After treatment, prostate-specific antigen (PSA) kinetics may show a transient rise (PSA bounce). Our aim was to investigate the association of PSA bounce with biochemical control.
Patients And Methods: Patients treated with BT in Switzerland were registered in a prospective database. Only patients with a follow-up of at least 2 years were included in our analysis. Clinical follow-up and PSA measurements were assessed after 1.5, 3, 6, and 12 months, and annually thereafter. If PSA increased, additional follow-up visits were scheduled. Cases of PSA bounce were defined as a rise of at least 0.2 ng/ml above the initial PSA nadir with a subsequent decline to or below the initial nadir without treatment. Biochemical failure was defined as a rise to nadir + 2 ng/ml.
Results: Between March 2001 and November 2010, 713 patients with prostate cancer undergoing BT with at least 2 years of follow-up were registered. Median follow-up time was 41 months. Biochemical failure occurred in 28 patients (3.9 %). PSA bounce occurred in 173 (24.3 %) patients; only three (1.7 %) patients with PSA bounce developed biochemical failure, in contrast to 25 (4.6 %) patients without previous bounce (p < 0.05). The median time to bounce was 12 months, the median time to biochemical failure was 30 months. The median bounce increase was 0.78 ng/ml. Twenty-eight patients with bounce (16.5 %) had a transient PSA rise of + 2 ng/ml above the nadir.
Conclusion: In most cases, an early increase in PSA after BT indicates PSA bounce and is associated with a lower risk of biochemical failure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00066-015-0860-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PSA bounce: understanding temporal fluctuations in prostate cancer after external radiotherapy.
Clin Transl Oncol
December 2024
Department of Medicine, School of Medicine and Haalth Sciences, Universitat Internacional de Catalunya, Josep Trueta s/n, 08195, Sant Cugat del Vallès, Spain.
Purpose: Prostate-specific antigen (PSA) bounce is a transient elevation in PSA levels commonly observed after radiotherapy. This study aims to investigate the characteristics, timing, and clinical implications of PSA bounce (PSA-B) in prostate cancer patients treated with external beam radiotherapy (EBRT), exploring potential causes and its relevance in patient management.
Materials And Methods: Between 2013 and 2019, 629 patients with localized prostate cancer were treated with EBRT.
High-dose-rate (2 fractions of 13.5 Gy) and low-dose-rate brachytherapy as monotherapy in prostate cancer. Long term outcomes and predictive value of nadir prostate-specific antigen.
Brachytherapy
December 2024
Radiation Oncology Department, Hospital Clínica Benidorm, Benidorm, Alicante, Spain.
Purpose: This study aims to evaluate the outcomes of patients treated for low-risk (LR) and favorable intermediate risk (FIR) prostate cancer with brachytherapy (BT) in monotherapy with LDR or HDR and its relationship with nadir PSA (nPSA).
Materials And Methods: We retrospectively analyzed 139 patients (2005-2019) with exclusive LDR (46%. 145/160 Gy) /HDR (54%.
Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost.
Brachytherapy
November 2024
Department of Oncology, Örebro University Hospital, Örebro, Sweden; Department of oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Introduction: Treating localized high-risk prostate cancer with a combination of external beam radiation therapy (EBRT) and high-dose-rate brachytherapy (HDR-BT) is a common approach. Moderately hypofractionated EBRT and a single HDR-BT boost simplifies the treatment. We aim to present our five-year results.
View Article and Find Full Text PDFProstate-specific antigen kinetics after stereotactic body radiotherapy for localized prostate cancer: A scoping review and meta-analysis.
Radiother Oncol
January 2025
Department of Radiation Oncology, University Hospital Bonn, Germany.
Purpose: Stereotactic body radiotherapy (SBRT) is emerging as a valuable treatment modality for localized prostate cancer, with promising biochemical progression-free survival rates. Longitudinal assessment of prostate-specific antigen (PSA) is the mainstay of follow-up after treatment. PSA kinetics and dynamics are well-established in the context of brachytherapy and conventionally fractionated radiotherapy, yet little is known in the context of prostate SBRT.
View Article and Find Full Text PDFProstate-specific antigen (PSA) nadir and experience of PSA bounce after low-dose-rate brachytherapy for prostate cancer predicts clinical failure.
Brachytherapy
November 2024
Department of Urology, Nara Medical University, Nara, Japan.
Article Synopsis
- The study investigated how prostate-specific antigen (PSA) levels and PSA bounce relate to cancer control after treatments like low-dose-rate brachytherapy (LDR-BT) and external beam radiotherapy (EBRT), with or without hormone therapy, while considering testosterone levels.
- Researchers examined 944 prostate cancer patients to determine the impact of PSA levels (specifically 0.1, 0.2, or 0.5 ng/mL) and the occurrence of PSA bounce over several years post-treatment using statistical models.
- Findings indicated that patients with normal testosterone who maintained lower PSA levels after treatment had significantly better outcomes in avoiding clinical failures, as did those who experienced a bounce in PSA levels during the early years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!